INDIANAPOLIS, May 22, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis…Original Article
Lilly’s Taltz (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area
